· JAMA 2021 · clinical practice guideline · n=?

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.

Level 5 - mechanism / opinion, no new human data

Clinical practice guideline statement synthesizing commissioned systematic reviews and simulation modeling.

PubMed 34003218 · doi:10.1001/jama.2021.6238 · record verified 2026-08-28

What was done

The US Preventive Services Task Force (USPSTF) updated its 2016 recommendation on screening for colorectal cancer in asymptomatic, average-risk adults. The USPSTF commissioned a systematic review evaluating the benefits and harms of screening in adults 40 years or older (including variations by age, sex, and race/ethnicity) and comparative modeling from the Cancer Intervention and Surveillance Modeling Network to estimate life-years gained, cases averted, and deaths averted across various starting and stopping ages.

What was found

The abstract reports that colorectal cancer incidence in adults aged 40 to 49 years increased by almost 15% from 2000-2002 to 2014-2016, and 10.5% of new cases occur in persons younger than 50 years. In 2016, 26% of eligible US adults had never been screened, and in 2018, 31% were not up to date. Specific numeric effect estimates for screening tests are not reported in the abstract. The USPSTF concluded: - High certainty of substantial net benefit for screening adults aged 50 to 75 years (A recommendation). - Moderate certainty of moderate net benefit for screening adults aged 45 to 49 years (B recommendation). - Moderate certainty of small net benefit for selective screening in adults aged 76 to 85 years (C recommendation).

Why it matters

This guideline expanded average-risk colorectal cancer screening by lowering the routine starting age from 50 to 45 years to address increasing disease incidence in younger populations.

Limits

The abstract provides no direct effect size numbers, confidence intervals, or counts of included studies and participants from the systematic review. Findings apply strictly to asymptomatic, average-risk individuals and exclude high-risk groups, such as those with prior adenomas or genetic syndromes.

Cited by